Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBP.L Regulatory News (CBP)

  • There is currently no data for CBP

Form 8 (OPD) - Nucleus Financial Platforms Limited

9 Dec 2022 07:00

RNS Number : 1347J
Nucleus Financial Platforms Limited
09 December 2022
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Nucleus Financial Platforms Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Curtis Banks Group plc

(d) Is the discloser the offeror or the offeree?

Offeror

(e) Date position held:

The latest practicable date prior to the disclosure

8 December 2022

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

ORDINARY SHARES OF 0.5p EACH

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

-

Nil

-

(2) Cash-settled derivatives:

 

Nil

-

Nil

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

-

Nil

-

TOTAL:

Nil

-

Nil

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Interests in ordinary shares of 0.5 pence each in Curtis Banks Group plc held by persons acting in concert with Nucleus Financial Platforms Limited

Name

Number of ordinary shares

Percentage of issued share capital (per cent.)

N/A

N/A

N/A

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

09 December 2022

Contact name:

Alice Dixie, Nucleus Financial Platforms Limited

Telephone number:

+44 (0)77 0255 5615

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEETPBPTMTBMBMT
Date   Source Headline
1st Dec 202212:58 pmGNWForm 8.3 - Octopus Investments - Curtis Banks Group plc
1st Dec 202212:00 pmRNSForm 8.5 (EPT/RI) - Curtis Banks Plc
1st Dec 20229:32 amRNSForm 8.5 (EPT/RI)
30th Nov 202212:00 pmRNSForm 8.5 (EPT/RI) - Curtis Bank Plc
30th Nov 202210:48 amRNSForm 8.5 (EPT/RI)
29th Nov 20225:12 pmRNSForm 8.3 - Curtis Banks Group plc
29th Nov 20221:17 pmGNWForm 8.3 - Octopus Investments - Curtis Banks Group plc
29th Nov 202212:00 pmRNSForm 8.5 (EPT/RI) - Curtis Bank Plc
29th Nov 20229:23 amRNSForm 8.3 - Curtis Banks Group plc
29th Nov 20229:10 amRNSForm 8.5 (EPT/RI)
28th Nov 20223:17 pmRNSForm 8.3 - Curtis Banks Group Plc
28th Nov 20222:26 pmRNSForm 8.3 - Curtis Banks Group Plc
28th Nov 20221:41 pmRNSForm 8.3 - Curtis Banks Group plc
28th Nov 20221:36 pmEQSForm 8.3 - Maitland Institutional Services Limited: Re Curtis Banks Group plc
28th Nov 20221:18 pmGNWForm 8.3 - Form 8.3 - Octopus Investments - Curtis Banks Group plc
28th Nov 202212:11 pmRNSForm 8.5 (EPT/RI) - Curtis Banks Plc
28th Nov 202210:44 amGNWRule 8.3 - [CURTIS BANKS GROUP PLC - 25 11 2022 - Opening Declaration] - (CGAML)
28th Nov 202210:23 amRNSForm 8.5 (EPT/RI)
28th Nov 20228:49 amRNSForm 8.3 - [Curtis Banks Group PLC]
25th Nov 20221:33 pmRNSStatement Regarding Curtis Banks Group PLC
25th Nov 20221:08 pmRNSForm 8.3 - Curtis Banks Group PLC
25th Nov 202211:41 amRNSStatement re Possible Offer
21st Nov 20224:50 pmRNSBoard changes
10th Nov 20226:20 pmRNSDirector Declaration
7th Oct 20225:36 pmRNSChairman's incentive plan
5th Oct 20221:50 pmRNSHolding(s) in Company
20th Sep 20227:00 amRNSDividend Timetable
8th Sep 20227:00 amRNSInterim Results
9th Aug 20227:00 amRNSDirectorate Change
20th Jul 20224:36 pmRNSPrice Monitoring Extension
1st Jul 20225:05 pmRNSDirector/PDMR Shareholding
17th Jun 20227:00 amRNSDirectorate Change
9th Jun 20224:48 pmRNSDirector/PDMR Shareholding
7th Jun 20222:38 pmRNSHolding(s) in Company
26th May 20226:37 pmRNSResult of AGM - CORRECTION
26th May 20224:30 pmRNSResult of Annual General Meeting
26th May 20227:00 amRNSAGM and Board appointments
29th Apr 20227:00 amRNSNotice of AGM
20th Apr 20225:27 pmRNSDirector/PDMR Shareholding
13th Apr 20224:42 pmRNSDirector/PDMR Dealing
31st Mar 20227:17 amRNSFinal Results
8th Feb 20225:28 pmRNSHolding(s) in Company
29th Dec 20217:00 amRNSHolding(s) in Company
24th Dec 202112:41 pmRNSSecond Price Monitoring Extn
24th Dec 202112:35 pmRNSPrice Monitoring Extension
17th Nov 20217:00 amRNSHolding(s) in Company
12th Nov 20214:41 pmRNSSecond Price Monitoring Extn
12th Nov 20214:36 pmRNSPrice Monitoring Extension
9th Nov 20214:41 pmRNSSecond Price Monitoring Extn
9th Nov 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.